HCP, Inc. (NYSE:HCP) has received an average recommendation of “Buy” from the twelve research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $36.78.
Several equities analysts recently issued reports on HCP shares. KeyCorp boosted their price target on HCP from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Wednesday, October 2nd. Morgan Stanley boosted their price target on HCP from $32.00 to $35.00 and gave the company an “equal weight” rating in a research report on Tuesday, September 17th. Scotiabank set a $38.00 price objective on HCP and gave the company a “buy” rating in a report on Monday, September 30th. JPMorgan Chase & Co. raised HCP from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $35.00 to $38.00 in a report on Tuesday, October 8th. Finally, Barclays lifted their price objective on HCP from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, October 2nd.
Shares of HCP stock opened at $34.49 on Friday. The stock has a market capitalization of $17.02 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 6.81 and a beta of 0.22. HCP has a 52-week low of $26.58 and a 52-week high of $37.93. The stock’s 50-day moving average price is $33.88 and its 200 day moving average price is $34.24. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.01.
Large investors have recently made changes to their positions in the company. Quest Capital Management Inc. ADV purchased a new stake in shares of HCP during the 3rd quarter worth approximately $28,000. Bartlett & Co. LLC purchased a new stake in shares of HCP during the 3rd quarter worth approximately $36,000. CSat Investment Advisory L.P. boosted its stake in shares of HCP by 77.6% during the 2nd quarter. CSat Investment Advisory L.P. now owns 1,165 shares of the real estate investment trust’s stock worth $37,000 after acquiring an additional 509 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of HCP by 29.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,364 shares of the real estate investment trust’s stock worth $49,000 after acquiring an additional 314 shares in the last quarter. Finally, North Star Investment Management Corp. purchased a new stake in shares of HCP during the 3rd quarter worth approximately $54,000. 95.80% of the stock is currently owned by institutional investors and hedge funds.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Featured Article: How to identify percentage decliners
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.